Unlabelled: Neoadjuvant chemotherapy (NAC) is a standard-of-care treatment for locally advanced triple negative breast cancer (TNBC) before surgery. The early assessment of TNBC response to NAC would enable an oncologist to adapt the therapeutic plan of a non-responding patient, thereby improving treatment outcomes while preventing unnecessary toxicities. To this end, a promising approach consists of obtaining in silico personalized forecasts of tumor response to NAC via computer simulation of mechanistic models constrained with patient-specific magnetic resonance imaging (MRI) data acquired early during NAC. Here, we present a new mechanistic model of TNBC growth and response to NAC, including an explicit description of drug pharmacodynamics and pharmacokinetics. As longitudinal in vivo MRI data for model calibration is limited, we perform a sensitivity analysis to identify the model mechanisms driving the response to two NAC drug combinations: doxorubicin with cyclophosphamide, and paclitaxel with carboplatin. The model parameter space is constructed by combining patient-specific MRI-based in silico parameter estimates and in vitro measurements of pharmacodynamic parameters obtained using time-resolved microscopy assays of several TNBC lines. The sensitivity analysis is run in two MRI-based scenarios corresponding to a well-perfused and a poorly perfused tumor. Out of the 15 parameters considered herein, only the baseline tumor cell net proliferation rate along with the maximum concentrations and effects of doxorubicin, carboplatin, and paclitaxel exhibit a relevant impact on model forecasts (total effect index, 0.1). These results dramatically limit the number of parameters that require in vivo MRI-constrained calibration, thereby facilitating the clinical application of our model.
Supplementary Information: The online version contains supplementary material available at 10.1007/s00366-023-01873-0.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607094 | PMC |
http://dx.doi.org/10.1007/s00366-023-01873-0 | DOI Listing |
BMC Gastroenterol
January 2025
Department of General Surgery (Gastrointestinal Surgery, Unit 1), The Sixth Affiliated Hospital, Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510655, China.
Purpose: The survival benefits of neoadjuvant chemotherapy (NAC) for locally advanced gastric cancer (LAGC) patients are inconsistent. This study aims to investigate how different tumor regression grades (TRG) influence the survival gains associated with NAC treatment.
Methods: This study compared the treatment outcomes of patients who underwent CSC (neoadjuvant chemotherapy - surgery - adjuvant chemotherapy) with those receiving traditional SC (surgery - adjuvant chemotherapy) treatment.
Sci Rep
January 2025
College of Horticulture and Plant Protection, Inner Mongolia Agricultural University, Hohhot, 010018, Inner Mongolia, China.
Pugionium cornutum (L.) Gaertn (P. cornutum) has strong tolerance to drought, salt and disease, but the tolerance mechanisms for such stresses in P.
View Article and Find Full Text PDFOral Oncol
January 2025
Division of Otolaryngology-Head and Neck Surgery, The George Washington University School of Medicine & Health Sciences, Washington DC, USA. Electronic address:
Background: The feasibility and outcomes of neoadjuvant doublet chemotherapy with cisplatin and docetaxel followed by surgical resection of residual disease (NAC + S) for patients with newly diagnosed, resectable p16 positive (+) oropharyngeal squamous cell carcinoma (OPSCC) has been reported from a single institution. Here, we report pathologic responses, need for adjuvant treatment and recurrence-free survival (RFS) following this treatment from a second large academic institution.
Methods: A retrospective cohort study of patients with p16 + OPSCC receiving NAC + S and risk-adjusted adjuvant treatment between January 2017 and March 2024 was performed.
Noise Health
January 2025
Department of Geriatric Health Internal Medicine, Qingdao Municipal Hospital, Qingdao 266000, China.
Objective: Evaluate the effect of white noise intervention on sleep quality and immunological indicators of patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).
Methods: From January 2020 to December 2022, 104 newly diagnosed female patients (the number of people who met the inclusion criteria) with breast cancer who were confirmed to be preoperative NAC by puncture pathology were selected for a randomised single-blind trial. The patients were randomly divided into an observation group and a control group, with 52 cases in each group.
Breast Cancer Res Treat
January 2025
Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, 34390, Faith, Istanbul, Turkey.
Purpose: This study aimed to determine estrogen receptor (ER) expression in stromal cells in postchemotherapy tumor bed (PCTB) and its relationship with tumor regression and tumor characteristics.
Methods: The study included 490 breast cancer patients who received neoadjuvant chemotherapy (NAC). We performed ER in stromal cells in all resection specimens and available pre-treatment core biopsy materials of 299 patients immunohistochemically.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!